A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy.
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 28 Jul 2024 Status changed from recruiting to completed.
- 24 Nov 2016 New trial record